Cardiovascular disease is the leading cause of mortality and disability in the western world. In the last years, the accumulation of evidence coming from both retrospective and prospective clinical studies has led to an increased interest in the potential role of mild hyperhomocysteinemia as a major, independent risk factor for cardiovascular disease. The present paper reviews the position of homocysteine in metabolism to understand the pathogenesis of hyperhomocysteinemia, as well as the clinical data pointing to its proposed role as an independent cardiovascular disease risk factor.
Introduction
Cardiovascular disease (CVD) is the leading cause of mortality and disability in the Western World. While hypertension, hypercholesterolemia, diabetes, obesity and smoking have received widespread publicity as risk factors, epidemiological data obtained over the last 30 years suggest that a number of new biological markers are associated with increased risk for CVD. These new markers are: (i) altered glucose metabolism; (ii) increased levels of molecules re¯ecting decreased ®brinolysis and increased activation of the coagulation cascade; (iii) hyperlipidemia; (iv) elevations in cell adhesion molecules and other markers of endothelial function; (v) elevations in molecules associated with infection, in¯ammation, and vascular remodelling; and (vi) hyperhomocysteinemia [1] .
The emergence of new risk factors for CVD and other major human illnesses used to be received with scepticism in the scienti®c community. However, the accumulation of evidence coming from both retrospective and prospective clinical studies has led to an increased interest in homocysteine as a major CVD risk factor in the last few years [2±5] . In order to understand the increased interest raised by homocysteine, the present paper reviews the position of homocysteine in intermediate metabolism and the clinical data pointing to its proposed role as an independent CVD risk factor.
Metabolism of homocysteine
Homocysteine is a sulphur-containing, nonproteinogenic amino acid biosynthesized from methionine that takes a key place between the folate cycle and the activated methyl cycle, and that has three main metabolic fates: to be remethylated to methionine, to enter the cysteine biosynthetic pathway, or to be released into the extracellular medium ( Fig. 1) .
Activated methyl cycle
In many biosynthetic reactions, a transfer of methyl groups is required. Tetrahydrofolate can behave as a carrier and donor of methyl groups, but its transfer potential is not high enough for most biosynthetic methylations. The universal activated methyl donor is S-adenosylmethionine, which is synthesized by the transfer of an adenosyl group from ATP to the sulphur atom of methionine in a nonequilibrium reaction. When S-adenosylmethionine transfers its methyl group to an acceptor, S-adenosylhomocysteine is formed. The hydrolysis of S-adenosylhomocysteine, catalysed by S-adenosylhomocysteine hydrolase, produces homocysteine and adenosine.
In the activated methyl cycle, homocysteine is remethylated to methionine in a reaction of transfer of a methyl group from 5-methyltetrahydrofolate, catalysed by methionine synthase, an enzyme which requires vitamin B 12 as a cofactor. This is the last point of the activated methyl cycle and the point shared with the folate cycle [6] . Tetrahydrofolate can accept one-carbon groups in either N-5 and/or N-10 nitrogen atoms. For instance, the transfer of a onecarbon group from serine produces glycine and N 5 ,N 10 -methylenetetrahydrofolate. This folate cycle is closed with the reaction catalysed by methylenetetrahydrofolate reductase, to produce N 5 -methyl-tetrahydrofolate.
In liver and kidney, a substantial proportion of homocysteine is remethylated by an alternative route in which betaine serves as a methyl donor for the reaction catalysed by betaine-homocysteine methyltransferase [6] .
Recently, an alternative pathway for the conversion of homocysteine into methionine has been proposed [7] . Homocysteine can be activated to homocysteine-tRNA. Why is homocysteine activated and attached to tRNA despite being a nonproteinogenic amino acid? Now it seems that homocysteine is the preferred amino acid for aminoacylation of initiator tRNA in eukaryotes. The homocysteine-activating enzyme resembles the bacterial methionine-tRNA synthetase in two ways: both acylate only mammalian initiator tRNA and both modify the Figure 1 Metabolism of homocysteine. DMG dimethylglycine, SAM, S-adenosylmethionine; SAH, S-adenosylhomocysteine; R, a general acceptor of methyl groups; A, adenine; THF, tetrahydrofolate. acylated initiator tRNA. In fact, homocysteine-tRNA is rapidly methylated to methionine-tRNA by a methylating factor, in a way analogous to the conversion of bacterial methionine-(initiator)tRNA to formyl-methionine-tRNA. This explains why activated homocysteine is not found in proteins. It is proposed that homocysteine thiolactone is formed when methylation of homocysteine-tRNA to methionine-tRNA does not work adequately, as is the case in several malignant cells defective in methionine metabolism [8] . Thus, these new ®ndings seem to show that homocysteine thiolactone formation is not a sign of homocysteine misactivation, but rather of inadequate methylation of homocysteine-tRNA to methionine-tRNA. Since in many cases N-terminal methionine is released from the polypeptide after chain maturation, homocysteine converted by this pathway can enter the cellular methionine pool.
Cysteine biosynthesis
Cysteine is biosynthesized from methionine through the socalled transsulphuration pathway. The ®rst three steps of this pathway are shared with the activated methyl cycle and render homocysteine from methionine. In the transsulphuration pathway, homocysteine is the substrate of the vitamin B 6 -dependent enzyme cystathionine b-synthase, which catalyses its condensation with serine to form cystathionine. This is the critical step in the pathway because it is irreversible under physiological conditions; from this point on, homocysteine is committed to follow this pathway. There is a tight regulation of homocysteine metabolism based upon the very different af®nities of methionine synthase and cystathionine b-synthase for homocysteine: the ®rst enzyme shows low K m values for homocysteine (below 0´1 mM), and the second one has high K m values for homocysteine (over 1 mM). Thus, at low homocysteine concentrations, methionine conservation is favoured; and at high homocysteine concentrations, immediate and long-term drainage of homocysteine via the transsulphuration pathway is ensured [9] . In the last step of the transsulphuration pathway, cystathionine is cleaved by cystathionase, another vitamin B 6 -dependent enzyme, to form 2-oxoglutarate and cysteine.
A study in rats has identi®ed the kidney as a major site for the removal and metabolism of homocysteine [10] . It seems that a metabolic channelling occurs leading this homocysteine, removed from the blood by the kidney, to be metabolized primarily through the transsulphuration pathway. In humans there are contradictory results: Hankey & Eikelboom [11] mention data supporting this hypothesis but Van Guldener et al. [12] show data contesting the hypothesis.
Homocysteine export
This is the third metabolic fate of homocysteine. Studies with isolated cells show that homocysteine export into the extracellular area re¯ects an imbalance between homocysteine production and metabolism, either at low or high homocysteine concentrations [9] . At low homocysteine concentrations, the activity of methionine synthase is critical for homocysteine export [13] ; for this reason, plasma total homocysteine is markedly increased with folate or vitamin B 12 de®ciency [14, 15] . On the other hand, at high homocysteine concentrations, the activity of cystathionine b-synthase in¯uences homocysteine export; for this reason, a de®ciency in this enzyme activity results in an abnormal response to methionine loading [16±18].
Obviously, this third metabolic fate of homocysteine is the direct cause of increased total homocysteine levels in plasma, and thus the most interesting one in the context of the study of hyperhomocysteinemia as a CVD risk factor.
Different forms of homocysteine in plasma
Human plasma contains both reduced and oxidized species of homocysteine. The thiol group of homocysteine allows it to form a disulphur bond with other homocysteine molecules (rendering homocystine), with free cysteine, or with thiol groups of plasma proteins, such as albumin. Oxidized forms comprise an overwhelming majority (up to 99%) and reduced homocysteine represents no more than 1% of total plasma homocysteine [5] . The sum of all the forms of homocysteine that exist in plasma is usually called total homocysteine.
Protein-bound homocysteine represents up to 75% of total homocysteine. Both experimental and clinical studies demonstrate the presence in plasma of binding sites for aminothiols, which interact preferentially with homocysteine. A rapid equilibrium exists between free and proteinbound homocysteine fractions in vivo. Thus, transitory increased free homocysteine levels, induced by an increase in homocysteine export or by methionine loading, become progressively bound to plasma protein in a redistribution which takes place in less than 24 h [19] .
It should be kept in mind that most homocysteine in stored plasma is present as a protein-bound fraction, which in the past made it dif®cult to develop a reliable and automatable method for homocysteinemia determination [9] .
Clinical interest of homocysteine as a CVD risk factor
Homocysteinuria was ®rst described in 1962 in mentally retarded children [20, 21] . Associations between this inborn disease and several pathologies, especially vascular pathologies, have been reported later [22±24] . Based on previous data [25] , in 1975 a homocysteine theory of atherosclerogenesis was formulated [26] . The ®rst study implying that moderately elevated homocysteinemia might be a new general CVD risk factor was published in 1976 [27] . However, during the next 15 years, this research area entered a latency phase, producing only a few isolated signi®cant contributions.
In the 1990s, the interest in the studies relating hyperhomocysteinemia to CVD increased, at least in part, because of methodological advances in the determination of total plasma homocysteine and a greater appreciation of the role of micronutrients in health and well-being [5] . In 1991, a high total plasma homocysteine concentration was ®nally recognized as an independent CVD risk factor [28] . From this date on, the publication rate on the subject has been exponentially increasing. Thus, in 1998 some 400 papers related to homocysteine were published. After the publication in the 1990s of dozens of retrospective and prospective clinical studies, it is currently widely accepted that high levels of total plasma homocysteine are indeed associated with an increased risk of CVD [3±5]. Here, we will only comment on four of these studies. They are especially relevant ones, owing to the sample sizes and the in¯uence of the journals in which they were published.
A meta-analysis, based on 27 studies including some 4000 patients was carried out by Boushey et al. and published in JAMA in 1995 [29] , leading to the conclusion that homocysteine is an independent, graded risk factor for atherosclerotic disease in the coronary, cerebral and peripheral vessels. Another study published in JAMA included thousands of men and women of the Nutrition Canada Survey cohort and concluded that low serum folate levels correlate with the risk of fatal coronary heart disease [30] . A third paper published in JAMA reports the ®rst results of the European Concerted Action Project on homocysteine and CVD, where it is concluded that the risk conferred by high plasma total homocysteine was similar and independent of the conventional risk factors [31] . The fourth study was carried out among patients with angiographically con®rmed coronary artery disease; this study, published in the New England Journal of Medicine, concluded that plasma total homocysteine levels are a strong predictor of mortality in these patients [32] .
Other clinical areas with interest in homocysteine
From 1985 on, the determination of plasma total homocysteine has been an analytical method used in the diagnosis and follow-up of folate or cobalamine de®ciencies [9] . Hyperhomocysteinemia has also been associated with pregnancy complications, neural tube defects, mental disorders, cognitive impairment in the elderly, psoriasis and some tumours [33±39]. In contrast, plasma concentrations of homocysteine are low in some patients with Down's syndrome and in most patients with hyperthyroidism [9, 40] .
Methods of measurement
As mentioned above, methodological advances were essential in the development of this research area. The ®rst study reporting homocystinuria included quantitative data; since total homocysteine concentrations were extremely high, the use of elemental chemical methods was enough. In the 1970s and early 1980s, the most extended methodology was the use of amino acid analysers [9, 27] . These methods were later substituted by radioenzyme assays, the use of gas chromatography-mass spectrometry and the more and more frequent use of protocols of precolumn derivatization, high-pressure liquid chromatography (HPLC) and uorescence detection or, alternatively, HPLC and electrochemical detection [41±45] . However, the most decisive step towards a generalization in the determination of homocysteine levels in the analysis laboratories of clinics perhaps has been the introduction of sensitive, completely automatable immunoassays [46, 47] . The results obtained with these methods show good correlation with those obtained with HPLC and gas chromatography-mass spectrometry methods [47±49].
Ranges of total homocysteine concentrations
On the basis of the different data reported, it can be concluded that normal concentrations of total homocysteine in plasma are in the range of 5±16 mmol L À1 , although perhaps 10 mmol L À1 should be considered the desirable upper limit, because it is possible to achieve this level by optimal nutrition with respect to folic acid and both vitamins B 6 
Factors in¯uencing homocysteine levels

Demographic factors
Age Homocysteinemia tends to increase with age.
Gender
Men show higher homocysteine levels than age-matched women. In women, homocysteine levels tend to increase after menopause, possibly leading to an increased risk of CVD. According to a 14-year prospective study including more than 80 000 women, an intake of folate and vitamin B 6 above the current recommended dietary allowance may be important in the primary prevention of CVD among women [50] .
Geographical distribution
As mentioned above, great differences in mean values of plasma total homocysteine can be observed in healthy people from various countries, ranging from minimum values of 6±7 mmol L À1 in Japan, France and Spain, and more than 13 mmol L À1 in South Africa. In the Mediterranean area, the medium basal homocysteinemia is lower than in most of the rest of the western world, a fact which correlates well with the lower incidence of CVD in this area. In fact, a study carried out in Spain among the adult population showed a basal homocysteinemia of only 7´1 6 2´3 mmol L À1 [3] . These intercountry differences are real and not due to noncomparable sampling and assay procedures, and they are probably not mainly due to variations in the prevalence of homocystinuria. However, it should be kept in mind that standardization in the methods of measurement of total homocysteine is far from being a current reality. Recently, a clear and signi®cant correlation between plasma total homocysteine levels in healthy people from different countries and CVD mortality has been shown [51] .
Genetic factors
Genetic predisposition to hyperhomocysteinemia is associated with inborn errors in the metabolism of homocysteine. There are three main genetic factors: abnormality in the transsulphuration pathway due to a diminished or absent cystathionine b-synthase activity, abnormal (absent or thermolabile variant) methylene-tetrahydrofolate reductase, or abnormal methionine synthase.
The most common of the genetic causes of severe hyperhomocysteinemia and congenital homocystinuria is homozygous de®ciency of cystathionine b-synthase. It is inherited as an autosomal recessive trait and it occurs in 1 out of 100 000 live births, giving rise to an increase of up to 40-fold in fasting total homocysteine [11] . Almost 50% of untreated homozygotes develop cardiovascular disease before the age of 30 years [52] . The heterozygous form (present at a frequency of 1 in 150 live births) is not associated with abnormal plasma homocysteine levels.
The most common enzyme defect associated with mild hyperhomocysteinemia is the C677T point mutation in the coding region of the gene for methylene-tetrahydrofolate reductase, which is associated with a thermolabile variant of the enzyme that has about half-normal activity [53] .
Renal function
Homocysteine increases with increased creatinine, not because of impaired urinary excretion but rather because of impaired metabolism of homocysteine by the kidney. Thus, total homocysteine levels are considerably higher in patients with chronic renal disease, and this fact could contribute to the high incidence of vascular complications in patients with chronic renal failure [11] .
Acquired determinants
Habits
Tobacco addiction, excessive alcohol or coffee drinking, and sedentary life are determinant habits of hyperhomocysteinemia [5] .
Nutrition
The main acquired determinant factor of hyperhomocysteinemia is a nutritional de®ciency of folate, or of vitamins B 6 or B 12 [3±5,9,11]
Disease states
Hypothyroidism and severe psoriasis are associated with increased homocysteine levels. There are also elevated levels of homocysteine in chronic renal failure, acute lymphoblastic leukaemia and some kinds of solid tumours [4,11,33±39] .
Transplants
A newly recognized form of acquired hyperhomocysteinemia is associated with heart transplantation [54, 55] . The ®rst report of hyperhomocysteinemia in heart transplant recipients appeared in 1994 [56] . More recently, blood cyclosporine concentration has been found to be the strongest predictor of total homocysteine levels in cardiac transplant recipients [57] . These data point to renal function as an important determinant in organ transplant recipients, since cyclosporine and other immunosuppresors are nephrotoxins.
Medication
The list of medicinal products leading to increased total homocysteine levels includes: azaribine, a vitamin B 6 antagonist; carbamazepine, which interferes with folate metabolism; oestrogen-containing oral contraceptives, which induce vitamin B 6 de®ciency; methotrexate, which depletes 5-methyl-tetrahydrofolate; nitrous oxide, which inactivates vitamin B12; and phenytoin, which interferes with folate metabolism [1, 4] .
Pathogenicity of hyperhomocysteinemia
Thirty years ago, McCully & Wilson suggested that homocysteine had a direct toxic effect on endothelial cells [26] . In experimental models of atherogenesis, an elevated plasma total homocysteine concentration acts in concert with dietary lipids to produce intimal lesions [58] . An alternative hypothesis to that of a direct effect of reduced homocysteine on endothelial cell injury is that homocysteine is acting indirectly through its oxidation and the concomitant production of reactive oxygen species [5] .
It has been shown that high levels of homocysteine induce a sustained injury on arterial endothelial cells which accelerates the development of thrombosis and atherosclerosis [59] . When laboratory animals were infused with 0´1±0´3 mM homocysteine, their arteries showed a thicker intima, proliferation of their smooth muscle cells, increased desquamation of the luminal surface and high levels of foam cells [60] . This proliferative effect of homocysteine on arterial smooth muscle cells is a relevant feature of atherosclerosis [61, 62] . In fact, homocysteine has been shown to increase DNA synthesis in vascular smooth muscle cells, while impeding the regeneration of damaged endothelial cells [63, 64] .
It has recently been reported that physiologically relevant concentrations of homocysteine (but not other thiols) in the presence of adenosine inhibited the growth of vascular endothelial cells by a mechanism involving a decreased carboxymethylation of p21 ras [65] . Homocysteine has been shown to modulate the expression of the enzymes glutathione peroxidase and nitric oxide synthase [66, 67] . These actions can be in connection with the widely believed capability of homocysteine to alter the surface properties of endothelial cells by changing their phenotype from anticoagulant to procoagulant [68] . In fact, physiological levels of homocysteine may enhance the binding of lipoprotein to ®brin [69] . On the other hand, high levels of homocysteine reduce protein C activation, thus inhibiting its anticoagulant activity [70] ; induce a great inhibition, by more than 75%, of antithrombin III [71] ; inhibit the synthesis of anticoagulant heparan sulphate through an induced alteration of the redox potential [72] ; suppress thrombomodulin and inactivate its co-factor activity [70, 73] ; block tissue plasminogen activator binding to endothelial cells [74] ; and activate tissue factor transcription [75] . Furthermore, it has been shown that homocysteine induces the activity of a protease which activates factor V, thus promoting coagulation even in the absence of thrombin [76] . Homocysteine rapidly reacts with nitric oxide to form S-nitroso-homocysteine, which acts as a potent antiplatelet agent; the formation of this adduct may attenuate the production of peroxides from homocysteine, thus protecting against the atherogenic properties of homocysteine. Vascular injury could be caused by an imbalance between nitric oxide production from dysfunctional endothelial cells and homocysteine concentrations [77] .
In a very recent paper, it has been shown that homocysteine fails to elicit an oxidative response in human umbilical vein endothelial cells [78] . This study indicates that the activation of stress response genes by homocysteine involves reductive stress leading to an altered function of the endoplasmic reticulum. These effects are fundamentally different from those of other endothelial cell perturbants known to cause oxidative damage. Since homocysteine also decreases the expression of the antioxidant enzyme glutathione peroxidase and natural killer-enhancing factor B, it has been proposed that homocysteine could potentially enhance the cytotoxic effects of agents or conditions known to cause oxidative stress.
Treatment
Vitamins B 6 and B 12 and folate are a simple, safe, ef®cient and economic means to reduce hyperhomocysteinemia [3±5]. However, there is no de®nitive consensus on the doses, pattern and time of treatment. There is de®nite evidence from short-term dietary supplementation trials that folic acid in doses from 0´5 to 5 mg day À1 can reduce homocysteine levels by 25% in individuals with average homocysteine levels. There is still some uncertainty about whether doses of folic acid of 0´4 or 0´8 mg day À1 have greater proportional effects than does 0´2 mg day À1 . Recently, it has been shown that 2 g of N-acetylcysteine twice a day for 2 weeks reduces basal homocysteine concentrations in plasma by up to 50% [79] . Randomized placebo-controlled clinical trials on the usefulness of folate treatment remain to be undertaken. Since there is little commercial interest and incentive to test such an inexpensive and nonpatentable treatment as folate intake, such trials should be undertaken by national and international public health services. As stated in an editorial in JAMA, further delays cannot be justi®ed [80] . In fact, currently some studies of secondary and primary prevention are in course to test whether a reduction in plasma total homocysteine levels correlates with a reduction in mortality and morbidity of CVD. There are at least seven large-scale clinical trials, involving more than 30 000 patients, to test the role of homocysteine in CVD.
Concluding remarks
Currently, hyperhomocysteinemia seems to be accepted as an important, independent CVD risk factor. However, the evidence needs to be strengthened by a systematic review of all comparable studies and the demonstration, in randomized trials, that lowering plasma total homocysteine levels correlates with a reduction in CVD [11] . The remarkable methodological advances introduced in the last few years, and mainly the availability of automatable, quantitative methods, allow for very precise, safe and fast determinations of plasma total homocysteine levels. However, the determination of total plasma homocysteine remains to be standardized. Only if both the strengthening of evidence mentioned above and the standardization of homocysteine measurement are achieved, will total homocysteine become an actual, useful marker of vascular risk. If so, the high prevalence of moderate hyperhomocysteinemia and the knowledge of the main acquired and genetic determinants, will make it an ideal target for intervention not only in vascular patients but also in the general population.
